Pharmacophysiology of atopic dermatitis.
Atopic dermatitis is clearly characterized by altered cutaneous physiologic responses. There is a tendency to acral vasoconstriction. Rubbing causes skin pallor and white dermographism. Vascular instability is demonstrated by responses to cholinergic agents, histamine, and nicotinates. Psychophysiologic studies demonstrate exaggerated vasodilator responses to emotional stress with consequent pruritus and scratching. The itch threshold is low, duration is prolonged, and nighttime scratching movements may be frequent or almost continuous. Regardless of the inciting trigger factors, the scratching causes the damage and the severe dermatitis. Thermal as well as emotional stimuli to sweating cause severe itching in AD, yet the concept of a miliaria-type, poral occlusion mechanism remains unproven. Some studies suggest actually increased sweating along with erythema and pruritus during acute flares of AD. The concept of sweat-borne allergens causing skin reactions during sweating is interesting but has never been proven. Studies of sweat responses to pharmacologic agents have produced conflicting data, and attempts to link these responses to Szentivanyi's beta-adrenergic blockade theory are not convincing. The numerous variables of climate, season, sex, age, and habitus affect sweating greatly. Future studies must carefully control for each of these factors before pharmacologically induced sweat responses can be interpreted clearly. A number of lines of evidence suggest involvement of histamine and other mediators in the evolution of erythema, pruritus, and scratching in AD. Flares of the condition have been reproducibly evoked by only two incitants: experimental emotional stress interviews and specific food challenge in selected sensitive individuals. In the latter, increased plasma histamine has been demonstrated, presumably generated by antigen/IgE stimulated degranulation of mast cells in the gut and/or skin. The demonstrated increased histamine releasability of basophils from atopic individuals may be the result of defective cellular regulatory mechanisms. Recent studies have demonstrated increased cyclic AMP-phosphodiesterase activity in leukocytes from atopic individuals. The resultant decreased intracellular cyclic AMP removes an inhibitory factor, which in turn causes net cellular hyperresponsiveness. This effect has been shown to account, at least in part, for increased histamine release from leukocytes of patients with AD. These and other studies focused upon cell functional regulation are providing better understanding of basic biochemical abnormalities and may lead to improved diagnostic and therapeutic approaches in managing atopic disease.
D001676:Biofeedback, Psychology / Q000502:physiology; D002395:Catecholamines / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism; D003876:Dermatitis, Atopic / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D005260:Female; D006632:Histamine / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D007975:Leukotriene B4 / Q000378:metabolism; D050356:Lipid Metabolism; D008598:Menstruation; D009539:Nicotinic Acids / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D011247:Pregnancy; D011537:Pruritus / Q000209:etiology / Q000503:physiopathology; D011970:Receptors, Histamine H2 / Q000502:physiology; D012867:Skin / Q000378:metabolism; D012881:Skin Temperature; D013545:Sweat Glands / Q000503:physiopathology; D013566:Sympathomimetics / Q000494:pharmacology; D013601:T-Lymphocytes / Q000648:ultrastructure; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D013961:Thyroid Gland / Q000503:physiopathology; D010566:Virulence Factors, Bordetella / Q000276:immunology
D002395:Catecholamines; D009539:Nicotinic Acids; D010277:Parasympathomimetics; D011970:Receptors, Histamine H2; D013566:Sympathomimetics; D010566:Virulence Factors, Bordetella; D007975:Leukotriene B4; D006632:Histamine; D000242:Cyclic AMP